LAUSR

Recently, the Omicron subvariant BF.7 (BA.5.2.1.7) has out-competed the earlier different lineages, sublineages, and subvariants of Omicron (B.1.1.529), including BA.2, BA.3, BA.1, BA.1.1, BA.2.12.1, BA.2.75, BA.2.75.2, BA.4, BA.4.6, BA.5, BQ.1, and BQ.1.1 (BA.4/5), owing to possessing additional genomic mutation, higher transmissibility, and signi fi cant immune evasion properties to overpower protection rendered by neutralization antibodies of coronavirus disease 2019 (COVID-19) vaccines and boosters as well as the ef fi cacy of immu-notherapeutics [antibodies, monoclonal antibodies (mAbs)], and potentially increasing reinfections [1 – 5] . BF.7 (BA.5.2.1.7) is a sublineage of Omicron variation BA.5. Of note, Chinese cities are af fl icted by BF.7, which is spreading rapidly in Beijing, and eventually this subvariant has also been reported from the USA, Brazil, UK, Belgium, Germany, France, China, Denmark, Norway, Mongolia, Japan, India, and other countries, raising alarming concerns throughout the world [1,6,7] . Chinese strategy to tackle the pandemic seems to have failed on numerous fronts, from possibly the usage of less effective vaccines to the zero-COVID policy, inadequate immunity from past severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, which probably did not